| Product Unit Size | Cost | Quantity | Stock |
|---|
AZD-9291 is an irreversible inhibitor of EGFR. It is approved for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in patients failing previous tyrosine kinase therapy, and more recently also in T790M negative NSCLC patients. Combination therapy with pemetrexed and cisplatin is currently being studied to delay or overcome resistance to AZD-9291 that is commonly experienced by patients after prolonged treatment.
| Cas No. | 1421373-65-0 |
|---|---|
| Purity | ≥99% |
| Formula | C28H33N7O2 |
| Formula Wt. | 499.62 |
| IUPAC Name | N-(2-{[2-(Dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino}phenyl)acrylamide |
| Synonym | AZD 9291, AZD9291, Osimertinib, Mereletinib |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Bollinger M., Agnew A., et al. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm PRact. 24(5):279-388 (2018). PMID: 28565936.
La Monica S., Minari R., Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. J Exp Clin Cancer Res. 38(1):222 (2019). PMID: 31138260.